Physician profile
Ilan Melnick
NPI 1427048115
$2,829,788.77
in general payments reported to CMS, 2019-2025
37 companies · $813K in 2025
The $813K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348K · 2020: $94K · 2021: $243K · 2022: $283K · 2023: $460K · 2024: $590K · 2025: $813K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.2M · Consulting Fee: $297K · Travel and Lodging: $250K · Honoraria: $94K · Food and Beverage: $46K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,165,117.81 |
| Consulting Fee | $296,586.58 |
| Travel and Lodging | $250,124.20 |
| Honoraria | $94,331.50 |
| Food and Beverage | $46,037.61 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,280.00 |
| Education | $117.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $690,114.51 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $654,604.79 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339,059.26 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $299,421.31 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $203,903.75 | 2022-2025 | Auvelity, Symbravo |
| E.R. Squibb & Sons, L.L.C. | $167,095.28 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $157,250.31 | 2019-2025 | Lybalvi, Aristada |
| H. Lundbeck A S | $104,780.34 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $32,098.29 | 2021-2025 | |
| Indivior INC. | $30,924.55 | 2019-2022 | |
| Noven Pharmaceuticals, INC. | $29,299.69 | 2020-2024 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $26,794.94 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $19,761.03 | 2020-2025 | Fanapt, Hetlioz |
| Boehringer Ingelheim International Gmbh | $11,748.33 | 2025 | |
| Biogen, INC. | $10,971.94 | 2022-2025 | Zurzuvae |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $10,902.13 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,750.40 | 2019-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $9,029.35 | 2022-2025 | Quviviq, Quviviq |
| Luye Pharma (USA) Ltd. | $6,158.06 | 2025 | Erzofri Extended-Release |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,747.36 | 2019-2025 | Abilify Asimtufii, Rejoyn, Rexulti |
| Sage Therapeutics, LLC | $4,746.01 | 2019-2023 | |
| Lundbeck LLC | $3,980.02 | 2019-2025 | Vyepti, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $1,266.34 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.07 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $277.76 | 2019-2024 | Nuplazid |
| Noven Therapeutics, LLC | $220.84 | 2020-2025 | Xelstrym |
| Allergan, INC. | $69.29 | 2020 | |
| Corium, LLC | $68.63 | 2023-2024 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $66.47 | 2021 | |
| Tris Pharma INC | $61.86 | 2023-2025 | Dyanavel Xr |
| Shire North American Group INC | $56.33 | 2019 | |
| Merck Sharp & Dohme LLC | $55.40 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $27.88 | 2023 | |
| Pfizer INC. | $22.57 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.08 | 2022 | |
| Neos Therapeutics, Lp | $15.99 | 2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $14.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilan Melnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.